Table 4 Detailed listing of concomitant medications and patient characteristics for the 3 patients with HDL-C reductions ≤30% at study endpoint
HDL-C (mmol/L) | Triglycerides (mmol/L) | Apo AI (g/L) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Concomitant Therapy | Age (yr) | Sex | BMI | Baseline | Endpoint (% change) | Baseline | Endpoint (% change) | Baseline | Endpoint (% change) |
Reduction between 30%-40% | ||||||||||
Feno | None | 36 | Male | <30 | 1.04 | 0.73 (-30.00) | 3.48 | 3.59 (3.25) | 1.26 | 1.23 (-2.38) |
Reduction between >40%-50% | ||||||||||
EZE+Feno | celecoxib | 43 | Female | <30 | 0.85 | 0.44 (-48.48) | 3.44 | 2.25 (-34.65) | 1.18 | 0.53 (-55.1) |
acetaminophen | ||||||||||
clonazepam | ||||||||||
chlorthalidone | ||||||||||
propanolol HCl | ||||||||||
Reduction over 50% | ||||||||||
Feno | acetaminophen acetylcysteine | 52 | Male | <30 | 1.07 | 0.47 (-56.63) | 1.94 | 3.27 (68.02) | 1.47 | 0.54 (-63.3) |
cetrimide+naphazoline nitrate+phenylephrine hydrochloride+prednisolone | ||||||||||
fenspiride hydrochloride | ||||||||||
bacitracin zinc + tixocortol pivalate | ||||||||||
oxomemazine | ||||||||||
ibuprofen | ||||||||||
telithromycin | ||||||||||
guaifenesin+oxomemazine+sodium benzoate | ||||||||||
allopurinol | ||||||||||
niaouli oil+quinine benzoate+thiamine HCl | ||||||||||
losartan potassium | ||||||||||